Skip to main content
Caplight Logo









Exogene

Exogene

Private
OxfordHealthcare & Life Scienceshttps://exogene.co.uk/

Last Round

Grant

Oct 15, 2025

Total Funding Raised

$5.55M

Company Overview

Exogene is a biotechnology company that utilizes an artificial intelligence platform for the discovery and development of T-cell receptor (TCR)-based cell therapies for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

T-cell receptor discoveryTCR discoveryprotein engineeringcancer immunotherapygenerative AIdrug discoverytechbiobiophysical simulationhigh-throughput screeninglab-in-the-loopcell therapyTCR affinity enhancementcomputational drug discoveryoncologyAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exogene Comparables

Compare Exogene with similar companies based on industry and business-model similarity.

Exogene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synteny
93%
Etcembly
91%
ImmunoScape
77%

Exogene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 15, 2025
Convertible DebtOct 10, 2025
SeedApr 28, 2022

Key People

Founding team and executive leadership

Andrea Mambrini

CTO Co-Founder

Founding Team

Federico Paoletti

CEO Co-Founder

Founding Team

Exogene Investors

Notable investors and investment history

Exogene investors
InvestorRounds
KQ LabsSeed
Selvedge VentureSeed
R42 GroupSeed
Entrepreneurs FirstSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2025

    Added Immunocore Ltd, a mid-market biotechnology company, as a customer.

  • Apr 28, 2022

    $2M round led by Selvedge Venture.

Exogene Filings

Explore SEC and related filing metadata, where available.

Exogene filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Exogene's valuation, stock price, and market status.

Is Exogene a public or private company?

Exogene is a private company.

What is the current stock price of Exogene?

Exogene is a private company with no public stock price. No recent secondary market data is available.

How much is Exogene worth (valuation)?

Valuation information for Exogene is not publicly available.

Can I buy Exogene stock?

Exogene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Exogene's last funding round?

Exogene's most recent funding round was Seed on April 28, 2022.

Who are the main investors in Exogene?

Key investors in Exogene include Selvedge Venture.

Will Exogene IPO soon?

No public IPO plans have been announced for Exogene.

How can I track Exogene secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exogene's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOxford
Employee Range14
Year Founded2019
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?